| Clinical and biological implications of driver mutations in myelodysplastic syndromes E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ... Blood, The Journal of the American Society of Hematology 122 (22), 3616-3627, 2013 | 2090 | 2013 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1929* | 2020 |
| Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ... New England Journal of Medicine 365 (15), 1384-1395, 2011 | 1473 | 2011 |
| Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes L Malcovati, U Germing, A Kuendgen, MG Della Porta, C Pascutto, ... Journal of clinical oncology 25 (23), 3503-3510, 2007 | 1318 | 2007 |
| Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ... Journal of Clinical Oncology 23 (30), 7594-7603, 2005 | 1151 | 2005 |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet L Malcovati, E Hellström-Lindberg, D Bowen, L Adès, J Cermak, ... Blood, The Journal of the American Society of Hematology 122 (17), 2943-2964, 2013 | 831 | 2013 |
| Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms L Malcovati, E Papaemmanuil, DT Bowen, J Boultwood, MG Della Porta, ... Blood, The Journal of the American Society of Hematology 118 (24), 6239-6246, 2011 | 603 | 2011 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 581 | 2020 |
| Molecular international prognostic scoring system for myelodysplastic syndromes E Bernard, H Tuechler, PL Greenberg, RP Hasserjian, JE Arango Ossa, ... NEJM evidence 1 (7), EVIDoa2200008, 2022 | 529 | 2022 |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 26 (10), 1549-1556, 2020 | 527 | 2020 |
| CD34+ and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure M Valgimigli, GM Rigolin, A Fucili, MD Porta, O Soukhomovskaia, ... Circulation 110 (10), 1209-1212, 2004 | 509 | 2004 |
| SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts L Malcovati, M Karimi, E Papaemmanuil, I Ambaglio, M Jädersten, ... Blood, The Journal of the American Society of Hematology 126 (2), 233-241, 2015 | 506 | 2015 |
| The genetic basis of myelodysplasia and its clinical relevance M Cazzola, MG Della Porta, L Malcovati Blood, The Journal of the American Society of Hematology 122 (25), 4021-4034, 2013 | 467 | 2013 |
| Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) L Malcovati, MG Della Porta, C Strupp, I Ambaglio, A Kuendgen, ... Haematologica 96 (10), 1433, 2011 | 399 | 2011 |
| Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome M Jadersten, L Malcovati, I Dybedal, M Giovanni Della Porta, R Invernizzi, ... Journal of Clinical Oncology 26 (21), 3607-3613, 2008 | 381 | 2008 |
| Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia E Such, U Germing, L Malcovati, J Cervera, A Kuendgen, MG Della Porta, ... Blood, The Journal of the American Society of Hematology 121 (15), 3005-3015, 2013 | 365 | 2013 |
| Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells A Pellagatti, M Cazzola, A Giagounidis, J Perry, L Malcovati, ... Leukemia 24 (4), 756-764, 2010 | 353 | 2010 |
| Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia J Boultwood, J Perry, A Pellagatti, M Fernandez-Mercado, ... Leukemia 24 (5), 1062-1065, 2010 | 343 | 2010 |
| Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative … F Passamonti, E Rumi, D Pietra, MGD Porta, E Boveri, C Pascutto, ... Blood 107 (9), 3676-3682, 2006 | 335 | 2006 |
| Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes MG Della Porta, L Malcovati, E Boveri, E Travaglino, D Pietra, C Pascutto, ... Journal of clinical oncology 27 (5), 754-762, 2009 | 328 | 2009 |
